The iKang Healthcare and Mayo Clinic-backed healthcare management platform has received $17.5m in a round that increased its overall funding to $30m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Gut microbiome medicine developer EnteroBiotix has been backed by University of Aberdeen in a round that brings its total to $3.2m.

Tempus has now raised a total of $520m, after adding $200m to its coffers in a Novo-backed series F round, secured at a $3.1bn valuation.

The SoftBank-backed on-demand therapy platform increased its overall funding to $110m with a round that was led by Revolution Growth.

Homecare robot developer Pillo Health has closed a Stanley Ventures-led round that included Samsung, Hikma and Hackensack Meridien Health System.

Thrive will commercialise a blood test for multiple early-stage cancers based on research at Johns Hopkins University, following a series A round backed by Blue Cross and Blue Shield Association.

Thrive will commercialise a blood test for multiple early-stage cancers based on research at Johns Hopkins University, following a series A round backed by Blue Cross and Blue Shield Association.

Precision MedCare will take its machine learning-powered liver fibrosis diagnosis platform to China for early-stage testing with a view to securing regulatory approval.

Kytopen, the developer of a cell therapy manufacturing platform based on MIT research, has been backed by MIT’s The Engine for a second time.